STOCK TITAN

Abeona (ABEO) Insider Files Rule 144 to Sell 44,274 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Abeona Therapeutics, Inc. (ABEO): The filer reports a proposed sale of 44,274 shares of common stock through Stifel Nicolaus & Company, to be executed on 09/29/2025 on Nasdaq with an aggregate market value of $238,792.00. The shares were acquired as 38,800 restricted stock units on 09/28/2025 and payment is noted as cash on 09/29/2025. The filing shows 51,156,736 shares outstanding for the issuer. The form also discloses a sale by Vishwas Seshadri of 69,420 shares on 07/09/2025 for $406,503.00. The notice contains the standard insider representation regarding material nonpublic information.

Positive

  • Rule 144 compliance: The filing provides required disclosure of an insider sale including broker, number of shares, and acquisition details
  • Transparency: Prior insider sale on 07/09/2025 is disclosed, allowing investors to see recent insider transactions

Negative

  • Insider monetization: Proposed sale of 44,274 shares may represent insider liquidity rather than long-term holding
  • Short holding period for these shares: RSUs were acquired on 09/28/2025 and proposed for sale on 09/29/2025

Insights

TL;DR: Insider plans to sell a small block of shares disclosed under Rule 144; routine compliance filing with limited market impact.

The Form 144 reports a proposed sale of 44,274 common shares with an indicated market value of $238,792, executed through a broker on Nasdaq. The shares derive from restricted stock units granted one day earlier, with cash payment noted. The filing meets Rule 144 disclosure requirements and documents a prior sale by an individual named Vishwas Seshadri. There is no financial performance or forward guidance in this filing; implications are limited to insider liquidity and disclosure compliance.

TL;DR: Disclosure appears complete for a Rule 144 sale; shows insider monetization but no admission of undisclosed adverse information.

The notice contains the required attestation that the seller is unaware of material nonpublic information and indicates the securities were acquired as RSUs. The filing documents transaction timing and broker details, supporting transparency around insider selling activity. Absent additional context on role or cumulative insider sales, this filing alone does not signal governance irregularities but is material for monitoring insider liquidity and potential dilution effects.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ABEO Form 144 disclose about the proposed sale?

It discloses a proposed sale of 44,274 Abeona (ABEO) common shares through Stifel Nicolaus on 09/29/2025 with aggregate market value $238,792.00.

How were the shares being sold acquired according to the filing?

The filing states 38,800 of the shares were acquired as restricted stock units on 09/28/2025 with payment noted as cash on 09/29/2025.

Does the filing show any recent insider sales for ABEO?

Yes; it records that Vishwas Seshadri sold 69,420 shares on 07/09/2025 for gross proceeds of $406,503.00.

Where will the proposed sale be executed?

The proposed sale is to be executed on Nasdaq via Stifel Nicolaus & Company Inc.

Does the filer assert possession of any undisclosed material information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Abeona Therapeut

NASDAQ:ABEO

ABEO Rankings

ABEO Latest News

ABEO Latest SEC Filings

ABEO Stock Data

276.38M
48.61M
5.78%
73.58%
17.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CLEVELAND